Healthcare entity
The clearest coverage concentration is regulation: 3 of 4 stories, with the rest divided among 1 other category. Of the tracked stories, 1 of 4 also mention Amgen, the most common co-covered peer. Their average consequence score of 7.5 runs above the beat's 6 for that window.
Last mentioned: 3d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is regulation: 3 of 4 stories, with the rest divided among 1 other category. Of the tracked stories, 1 of 4 also mention Amgen, the most common co-covered peer. Their average consequence score of 7.5 runs above the beat's 6 for that window. The 177-day window averages about 0.2 stories each week. Source depth averages 3.3 original sources per story, versus 3.5 across the same-window beat baseline. Merck & Co. appears in 4 tracked Healthcare stories published from February 25, 2026 through August 20, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 1130 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck & Co.. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Cliff
Merck faces the loss of exclusivity for its top-selling cancer immunotherapy.
FDA approves Merck's Lipfendra
The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
Expected Closing
Anticipated completion of the acquisition following regulatory reviews.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Acquisition Announcement
Merck announces definitive agreement to buy Terns for $6.7 billion.
Clinical Progress
Terns Pharmaceuticals advances TERN-701 through early-stage clinical trials for CML.
A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
Merck has reached a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising Phase 2 leukemia treatment. The cash deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
A coalition of 15 Democratic-led states has filed a lawsuit against the Trump administration to block changes that reduce the recommended childhood vaccine schedule. The plaintiffs argue that the policy shift ignores scientific consensus and poses a significant risk of infectious disease outbreaks across the country.
Merck & Co. is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
